<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684331</url>
  </required_header>
  <id_info>
    <org_study_id>SJ-490</org_study_id>
    <nct_id>NCT02684331</nct_id>
  </id_info>
  <brief_title>CMR in Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>Cardiac Magnetic Resonance Imaging in Type 2 Diabetes Mellitus: The Mechanisms of Cardiac Function and Perfusion Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Slagelse Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Slagelse Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be performed as a cross-sectional survey. 300 Type 2 diabetes patients (T2DM),
      with or without known cardiovascular disease, will be recruited from the diabetes outpatient
      clinic, Slagelse Hospital. The patients will undergo echocardiography, Cardiac magnetic
      resonance imaging (CMR), clinical examination and will be asked to fill out questionnaires.

      This study project sets out to answer the following hypotheses:

        1. Patients with T2DM have an increased risk of developing diastolic dysfunction. Using
           CMR, the investigators wish to measure left ventricle peak filling rate and passive
           atrial emptying fraction as a measure of cardiac diastolic function. The investigators
           hypothesize that classic T2DM markers such as levels of urinary albumin excretion,
           retinopathy, autonomic neuropathy, hypertension, dyslipidemia, elevated HgbA1c, T2DM
           duration, etc. are associated with pathological findings by CMR.

        2. Patients with T2DM have impaired left ventricle myocardial perfusion as determined by
           gadolinium contrast CMR. The investigators hypothesize that the classic markers and risk
           factors mentioned above, are associated with left ventricle myocardial hypoperfusion as
           determined by gadolinium contrast CMR.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>On CMR; left ventricle peak filling rate (ml/s)</measure>
    <time_frame>Cross-sectional so at baseline</time_frame>
    <description>Measure for cardiac diastolic function; including measurements at rest and after glycopyrrolate chronotropic stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On CMR, LV myocardial perfusion</measure>
    <time_frame>Cross-sectional so at baseline</time_frame>
    <description>Including measurements at rest and with Adenosin stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>On CMR; passive atrial emptying fraction (%) as a measure for cardiac diastolic function</measure>
    <time_frame>Cross-sectional so at baseline</time_frame>
    <description>Measure for cardiac diastolic function; including measurements at rest and after glycopyrrolate chronotropic stress</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Cross-sectional so at baseline</time_frame>
    <description>Systolic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blod samples</measure>
    <time_frame>Cross-sectional so at baseline</time_frame>
    <description>NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Cross-sectional so at baseline</time_frame>
    <description>Diastolic function</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>T2DM</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance Imaging (CMR)</intervention_name>
    <description>An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.</description>
    <arm_group_label>T2DM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Standard measurements and strain.</description>
    <arm_group_label>T2DM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bood samples</intervention_name>
    <description>HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3</description>
    <arm_group_label>T2DM</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA-plasma Heparin-plasma Serum urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        300 T2DM patients, with or without known cardiovascular disease, will be recruited from the
        diabetes outpatient clinic, Slagelse Hospital.

        The patients will be divided into groups depending on their diabetes complication status.
        Individual groups of patients with fx. +/- retinopathy, +/- autonomous neuropathy, +/-
        hypertension, normo-/mikro-/makroalbuminuria will be compared.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient fully capable of informed consent

          -  Informed consent

          -  T2DM

          -  Age 18-80 (both years included)

        Exclusion Criteria:

          -  Contraindications to CMR (pacemakers/ICD-units, cochlear implants)

          -  Lack of consent

          -  Atrial fibrillation

          -  eGFR &lt; 30 ml/min/1,73m2 (only exclusion criteria for gadolinium contrast study)

          -  Women of childbearing potential who are not on acceptable contraception

          -  Severe claustrophobia (only contraindication for CMR but can undergo echocardiography
             and other examinations)

          -  Contraindications to adenosine: history of significant bronchial asthma, 2nd or 3rd
             degree AV-block, severe hypotension, long QT-syndrome, unstable angina pectoris, sinus
             node dysfunction, incompensated heart failure

          -  Contraindications to glycopyrrolate: closed-angle glaucoma, prostate hyperplasia,
             tachycardia, bladder atony, cardia insufficiency, non-congenital pylorus stenosis and
             gastroparesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin H Soerensen, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Slagelse Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter H Gaede, DMSc</last_name>
    <phone>+45 23959055</phone>
    <email>phgo@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annemie S Bojer, DM</last_name>
    <phone>+45 22857526</phone>
    <email>asph@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The diabetes outpatient clinic, Slagelse Hospital, Denmark</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter H Gaede, DMSc</last_name>
      <phone>+45 23959055</phone>
      <email>phgo@regionsjaelland.dk</email>
    </contact>
    <contact_backup>
      <last_name>Annemie S Bojer, DM</last_name>
      <phone>+45 22857526</phone>
      <email>asph@regionsjaelland.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Martin H Soerensen, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Slagelse Hospital</investigator_affiliation>
    <investigator_full_name>Annemie Stege Bojer</investigator_full_name>
    <investigator_title>Clinical assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

